Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial

Marc E Mooney, David V. Herin, Sheila M Specker, David Babb, Frances R. Levin, John Grabowski

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Amphetamine analogs have been demonstrated to have some efficacy in reducing use in cocaine dependent individuals. However, these agents also have potential for abuse. Lisdexamfetamine (LDX), a lysine + dextroamphetamine formulation, has been approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and as a prodrug, has less abuse potential. Objective: This pilot study sought to evaluate the safety, tolerability, and efficacy of LDX as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled parallel group study served to evaluate LDX in 43 cocaine-dependent individuals: (1) placebo (PBO; 0 mg, n= 21), (2) LDX (70 mg, n= 22). Participants received medication for 14 weeks. Cocaine use was determined based on urine analysis for benzoylecgonine (BE; a cocaine metabolite). Results: Retention rates were higher though not significantly different in the PBO (71.4%) than the LDX condition (57.1%). Compared to those in the PBO condition, those receiving LDX were more likely to report experiencing (ps < 0.05) diarrhea (45.5% vs. 14.3%), headaches (45.5% vs. 9.5%), and anxiety (31.8% vs. 4.8%). No differences in medication conditions were observed for blood pressure, heart rate, or body weight. In the randomized sample, no differences in cocaine use were seen. Those receiving LDX reported significantly less craving for cocaine than participants receiving PBO. Conclusions: LDX did not significantly reduce cocaine use compared to PBO in the randomized sample.

Original languageEnglish (US)
Pages (from-to)94-103
Number of pages10
JournalDrug and alcohol dependence
Volume153
DOIs
StatePublished - Aug 1 2015

Fingerprint

Cocaine
Placebos
Cocaine-Related Disorders
Dextroamphetamine
Lisdexamfetamine Dimesylate
Blood pressure
Prodrugs
Amphetamine
Attention Deficit Disorder with Hyperactivity
Metabolites
Lysine
Headache
Diarrhea
Anxiety
Heart Rate
Body Weight
Urine
Blood Pressure
Safety
Therapeutics

Keywords

  • Agonist-like treatment
  • Amphetamine analogs
  • Cocaine
  • Dextroamphetamine
  • Lisdexamfetamine dimesylate
  • l-Lysine-dextroamphetamine

Cite this

Pilot study of the effects of lisdexamfetamine on cocaine use : A randomized, double-blind, placebo-controlled trial. / Mooney, Marc E; Herin, David V.; Specker, Sheila M; Babb, David; Levin, Frances R.; Grabowski, John.

In: Drug and alcohol dependence, Vol. 153, 01.08.2015, p. 94-103.

Research output: Contribution to journalArticle

@article{41ceb4c441dd4d74b55e13c7d2aec472,
title = "Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial",
abstract = "Background: Amphetamine analogs have been demonstrated to have some efficacy in reducing use in cocaine dependent individuals. However, these agents also have potential for abuse. Lisdexamfetamine (LDX), a lysine + dextroamphetamine formulation, has been approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and as a prodrug, has less abuse potential. Objective: This pilot study sought to evaluate the safety, tolerability, and efficacy of LDX as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled parallel group study served to evaluate LDX in 43 cocaine-dependent individuals: (1) placebo (PBO; 0 mg, n= 21), (2) LDX (70 mg, n= 22). Participants received medication for 14 weeks. Cocaine use was determined based on urine analysis for benzoylecgonine (BE; a cocaine metabolite). Results: Retention rates were higher though not significantly different in the PBO (71.4{\%}) than the LDX condition (57.1{\%}). Compared to those in the PBO condition, those receiving LDX were more likely to report experiencing (ps < 0.05) diarrhea (45.5{\%} vs. 14.3{\%}), headaches (45.5{\%} vs. 9.5{\%}), and anxiety (31.8{\%} vs. 4.8{\%}). No differences in medication conditions were observed for blood pressure, heart rate, or body weight. In the randomized sample, no differences in cocaine use were seen. Those receiving LDX reported significantly less craving for cocaine than participants receiving PBO. Conclusions: LDX did not significantly reduce cocaine use compared to PBO in the randomized sample.",
keywords = "Agonist-like treatment, Amphetamine analogs, Cocaine, Dextroamphetamine, Lisdexamfetamine dimesylate, l-Lysine-dextroamphetamine",
author = "Mooney, {Marc E} and Herin, {David V.} and Specker, {Sheila M} and David Babb and Levin, {Frances R.} and John Grabowski",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.drugalcdep.2015.05.042",
language = "English (US)",
volume = "153",
pages = "94--103",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Pilot study of the effects of lisdexamfetamine on cocaine use

T2 - A randomized, double-blind, placebo-controlled trial

AU - Mooney, Marc E

AU - Herin, David V.

AU - Specker, Sheila M

AU - Babb, David

AU - Levin, Frances R.

AU - Grabowski, John

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: Amphetamine analogs have been demonstrated to have some efficacy in reducing use in cocaine dependent individuals. However, these agents also have potential for abuse. Lisdexamfetamine (LDX), a lysine + dextroamphetamine formulation, has been approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and as a prodrug, has less abuse potential. Objective: This pilot study sought to evaluate the safety, tolerability, and efficacy of LDX as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled parallel group study served to evaluate LDX in 43 cocaine-dependent individuals: (1) placebo (PBO; 0 mg, n= 21), (2) LDX (70 mg, n= 22). Participants received medication for 14 weeks. Cocaine use was determined based on urine analysis for benzoylecgonine (BE; a cocaine metabolite). Results: Retention rates were higher though not significantly different in the PBO (71.4%) than the LDX condition (57.1%). Compared to those in the PBO condition, those receiving LDX were more likely to report experiencing (ps < 0.05) diarrhea (45.5% vs. 14.3%), headaches (45.5% vs. 9.5%), and anxiety (31.8% vs. 4.8%). No differences in medication conditions were observed for blood pressure, heart rate, or body weight. In the randomized sample, no differences in cocaine use were seen. Those receiving LDX reported significantly less craving for cocaine than participants receiving PBO. Conclusions: LDX did not significantly reduce cocaine use compared to PBO in the randomized sample.

AB - Background: Amphetamine analogs have been demonstrated to have some efficacy in reducing use in cocaine dependent individuals. However, these agents also have potential for abuse. Lisdexamfetamine (LDX), a lysine + dextroamphetamine formulation, has been approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and as a prodrug, has less abuse potential. Objective: This pilot study sought to evaluate the safety, tolerability, and efficacy of LDX as a candidate treatment for cocaine dependence. Methods: A randomized, double-blind, placebo-controlled parallel group study served to evaluate LDX in 43 cocaine-dependent individuals: (1) placebo (PBO; 0 mg, n= 21), (2) LDX (70 mg, n= 22). Participants received medication for 14 weeks. Cocaine use was determined based on urine analysis for benzoylecgonine (BE; a cocaine metabolite). Results: Retention rates were higher though not significantly different in the PBO (71.4%) than the LDX condition (57.1%). Compared to those in the PBO condition, those receiving LDX were more likely to report experiencing (ps < 0.05) diarrhea (45.5% vs. 14.3%), headaches (45.5% vs. 9.5%), and anxiety (31.8% vs. 4.8%). No differences in medication conditions were observed for blood pressure, heart rate, or body weight. In the randomized sample, no differences in cocaine use were seen. Those receiving LDX reported significantly less craving for cocaine than participants receiving PBO. Conclusions: LDX did not significantly reduce cocaine use compared to PBO in the randomized sample.

KW - Agonist-like treatment

KW - Amphetamine analogs

KW - Cocaine

KW - Dextroamphetamine

KW - Lisdexamfetamine dimesylate

KW - l-Lysine-dextroamphetamine

UR - http://www.scopus.com/inward/record.url?scp=84937640146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937640146&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2015.05.042

DO - 10.1016/j.drugalcdep.2015.05.042

M3 - Article

C2 - 26116930

AN - SCOPUS:84937640146

VL - 153

SP - 94

EP - 103

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

ER -